Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy

Journal of Human Hypertension

Volumn 29, Issue 4, 2015, Pages 241-246

  Gupta, A ^a   Schiros, C G ^a   Gaddam, K K ^a   Aban, I ^b   Denney, T S ^c   Lloyd, S G ^a,d   Oparil, S ^a   Dell'Italia, L J ^a,d   Calhoun, D A ^a   Gupta, H ^a,d,e  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c AUBURN UNIVERSITY   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; COLLAGEN TYPE 1; MINERALOCORTICOID RECEPTOR; PROCOLLAGEN C PROTEINASE; SPIRONOLACTONE; BIOLOGICAL MARKER; COLLAGEN; MINERALOCORTICOID ANTAGONIST;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HUMAN TISSUE; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MALE; MIDDLE AGED; RESISTANT HYPERTENSION; BLOOD; BLOOD PRESSURE; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; DIASTOLE; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

ADULT; BIOMARKERS; BLOOD PRESSURE; CASE-CONTROL STUDIES; COLLAGEN; DIASTOLE; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84924764111     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2014.83     Document Type: Article

References (27)

1. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
2. Drazner MH. The progression of hypertensive heart disease. Circulation 2011; 123:327-334.
3. Leopold JA. Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling. Circulation 2011; 124: e466-e468.
4. Berk BC, Fujiwara K, Lehoux S. Ecm remodeling in hypertensive heart disease. J Clin Invest 2007; 117: 568-575.
5. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz 2000; 25: 299-306.
6. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992; 120: 893-901.
7. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the ALDO-DHF randomized controlled trial. JAMA 2013; 309: 781-791.
8. Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011; 162: 966-972.
9. Cleland JG, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail 1999; 1: 211-217.
10. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003; 362: 777-781.
11. Yamamoto K, Origasa H, Hori M on behalf of the J-DHF investigators. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013; 15: 110-118.
12. Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension 2010; 55: 1137-1142.
13. Ahmed MI, Desai RV, Gaddam KK, Venkatesh BA, Agarwal S, Inusah S et al. Relation of torsion and myocardial strains to LV ejection fraction in hypertension. JACC Cardiovasc Imaging 2012; 5: 273-281.
14. Feng W, Nagaraj H, Gupta H, Lloyd SG, Aban I, Perry GJ et al. A dual propagation contours technique for semi-automated assessment of systolic and diastolic cardiac function by CMR. J Cardiovasc Magn Reson. 2009; 11: 30.
15. Khalifa A, Youssef AB, Osman N. Improved harmonic phase (HARP) method for motion tracking a tagged cardiac MR images. Conf Proc IEEE Eng Med Biol Soc 2005; 4: 4298-4301.
16. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001; 104: 1248-1254.
17. Aeschbacher BC, Hutter D, Fuhrer J, Weidmann P, Delacretaz E, Allemann Y. Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. Am J Hypertens 2001; 14: 106-113.
18. Graettinger WF, Neutel JM, Smith DH, Weber MA. Left ventricular diastolic filling alterations in normotensive young adults with a family history of systemic hypertension. Am J Cardiol 1991; 68: 51-56.
19. Kitzman DW, Sheikh KH, Beere PA, Philips JL, Higginbotham MB. Age-related alterations of doppler left ventricular filling indexes in normal subjects are independent of left ventricular mass, heart rate, contractility and loading conditions. J Am Coll Cardiol 1991; 18: 1243-1250.
20. Kato S, Spinale FG, Tanaka R, Johnson W, Gt Cooper, Zile MR. Inhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic function. Am J Physiol 1995; 269: H863-H868.
21. Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC et al. Serum carboxyterminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101: 1729-1735.
22. Krum H, Elsik M, Schneider HG, Ptaszynska A, Black M, Carson PE et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail 2011; 4: 561-568.
23. Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, Dawkins IR, Murphy NF et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009; 54: 1674-1682.
24. du Cailar G, Fesler P, Ribstein J, Mimran A. Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system. Hypertension2010; 56: 865-870.
25. Dell'Italia LJ. Translational success stories: angiotensin receptor 1 antagonists in heart failure. Circ Res 2011; 109: 437-452.
26. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2013; 62: e147-e239.
27. Wan SH, Vogel MW, Chen HH. Pre-clinical diastolic dysfunction. J Am Coll Cardiol 2014; 63: 407-416.